某种肠道细菌
肿瘤微环境
生物
肠道菌群
失调
肝细胞癌
癌症研究
免疫学
癌症
肝硬化
免疫系统
炎症
医学
内科学
遗传学
作者
Kai Markus Schneider,Antje Mohs,Wenfang Gui,Eric Galvez,Lena Susanna Candels,Lisa Hoenicke,Uthayakumar Muthukumarasamy,Christian H. Holland,Carsten Elfers,Konrad Kilic,Carolin V. Schneider,Robert Schierwagen,Pavel Strnad,Theresa H. Wirtz,Hanns–Ulrich Marschall,Eicke Latz,Benjamin Lelouvier,Julio Sáez-Rodríguez,Willem M. de Vos,Till Strowig,Jonel Trebicka,Christian Trautwein
标识
DOI:10.1038/s41467-022-31312-5
摘要
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, and therapeutic options for advanced HCC are limited. Here, we observe that intestinal dysbiosis affects antitumor immune surveillance and drives liver disease progression towards cancer. Dysbiotic microbiota, as seen in Nlrp6-/- mice, induces a Toll-like receptor 4 dependent expansion of hepatic monocytic myeloid-derived suppressor cells (mMDSC) and suppression of T-cell abundance. This phenotype is transmissible via fecal microbiota transfer and reversible upon antibiotic treatment, pointing to the high plasticity of the tumor microenvironment. While loss of Akkermansia muciniphila correlates with mMDSC abundance, its reintroduction restores intestinal barrier function and strongly reduces liver inflammation and fibrosis. Cirrhosis patients display increased bacterial abundance in hepatic tissue, which induces pronounced transcriptional changes, including activation of fibro-inflammatory pathways as well as circuits mediating cancer immunosuppression. This study demonstrates that gut microbiota closely shapes the hepatic inflammatory microenvironment opening approaches for cancer prevention and therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI